Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

American Journal of Transplantation

Volumn 3, Issue 1, 2003, Pages 68-73

  Meier Kriesche, Herwig Ulf ^a   Steffen, Bettina J ^b   Hochberg, Alan M ^b   Gordon, Robert D ^b   Liebman, Michael N ^b   Morris, Jonathan A ^b   Kaplan, Bruce ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute rejection; Azathioprine; Immunosuppression; Kidney transplantation; Mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; RISK ASSESSMENT;

AFRICAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 0346525123     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.30112.x     Document Type: Article

References (17)

1. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
2. The U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
3. Almond PS, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-757.
4. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agoda LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
5. Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplantation 1999; 68: 1200-1203.
6. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (tl/2). Transplantation 1994; 57: 857-859.
7. Burke JF, Pirsch JD, Ramos EL et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994: 331: 358-363.
8. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988-1996. N Engl J Med 2000; 342: 605-612.
9. Rush DN, Jeffery JR, Gough J. Sequential protocol biopsies in renal transplant patients: clinico-pathological correlations using the Banff schema. Transplantation 1995; 59: 511-514.
10. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
11. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results form the placebo-controlled trial. Transplantation 1999; 68: 391-396.
12. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34:296-303.
13. Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409.
14. Schnitzler MA, Craig KE, Woodward RS, Lowell JA, Brennan DC. A contemporaneous comparison of MMF and AZA in the USRDS data base [abstract]. Chicago, IL: American Transplant Congress, 2001: 870A.
15. Dudley CRK and the MMF 'Creeping Creatinine' Study Group. MMF substitution for CSA is an effective and safe treatment of chronic allograft dysfunction; results of a multi-center randomized controlled study [abstract]. Am J Transplant 2002; S3: 41A.
16. Meier-Kriesche HU, Ojo A, Magee JC et al. African-American renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies. Transplantation 2000; 70: 375-379.
17. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. Transplantation 2001; 71: 1091-1097.